Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: Latest evidence and therapeutic implications

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

Renal cell cancer (RCC) continues to be among the most lethal malignancies in the USA. Introduction of anti-vascular epidermal growth factor receptor tyrosine kinase inhibitors over a decade ago resulted in improvement in disease outcomes, but further development of new therapies largely stagnated for many years. More recently, a better understanding of disease biology and treatment-resistance patterns has led to a second renaissance in drug development, with the anti-programmed cell death protein 1 immune checkpoint inhibitor, nivolumab, paving the way for additional therapies entering clinical trial testing in the treatment of RCC.

Original languageEnglish
Pages (from-to)287-298
Number of pages12
JournalTherapeutic Advances in Medical Oncology
Volume9
Issue number4
DOIs
StatePublished - 1 Apr 2017

Keywords

  • clear cell
  • immunotherapy
  • renal cell carcinoma
  • targeted therapies
  • vascular epidermal growth factor

Fingerprint

Dive into the research topics of 'Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: Latest evidence and therapeutic implications'. Together they form a unique fingerprint.

Cite this